Focus Stocks
Amgen near Resistance
Published on Monday, 06 February 2012 07:40 Written by Danny Miller
New York, February 6th (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) are trading very close to calculated resistance at $69.63 with the current price action closing at just $69.28 placing the stock near levels that make it difficult to buy.
Amgen Inc. (NASDAQ:AMGN) develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The company concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
Amgen's current stock range is defined by current calculated support defined at $56.00 and by the resistance level at $69.63, the stock is clearly over-extended from support, making it difficult to establishing new long positions at this level.
Traders don't have a clear entry point for Amgen, as the stock is well above support, however, as the stock pulls back towards $56.00 it will definitely provide a reference point to establish a trade. On the other hand if the stock decides to break above resistance level at $69.63 then traders will get an opportunity to enter Amgen stock by establishing a position as the stock moves to a higher range.
Related Articles
- Approaching Resistance: Amgen
- Amgen Is Close to the 50 Day Moving Average
- Amgen Is Close to the 50 Day Moving Average
- Amgen Is Close to Resistance
- Amgen Is Close to the 50 Day Moving Average
- Approaching Resistance: Amgen
- Amgen Broke Resistance
- Is Amgen Closing in to Resistance?
- Biotech Laggard
- Is Amgen Closing in to Resistance?
Related Partner Headlines
- Amgen Inc (AMGN): Today's Featured Drugs Loser - TheStreet.com
- From Earlier: Amgen Announces Analysis Of Rilotumumab Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - Benzinga
- From Earlier: Amgen Announces Analysis Of Rilotumumab Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - Benzinga
- From Earlier: Amgen Announces Analysis Of Rilotumumab Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - Benzinga
- Amgen Stock To Go Ex-dividend Monday (AMGN) - TheStreet.com
- Amgen Inc (AMGN): Today's Featured Drugs Winner - TheStreet.com
- Amgen Reaches New 52-Week High (AMGN) - TheStreet.com
- Benzinga's M&A Chatter for Wednesday April 25, 2012 - Benzinga
- Amgen Goes to Turkey, Loses Biotech Cred - TheStreet.com
- From Earlier: Amgen to Acquire Mustafa Nevzat; Company Valued at $700M - Benzinga
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Mixed Signals Emerge From Bakken Shale - TheStreet.com -
The Five Dumbest Things on Wall Street This Week: May 25 - TheStreet.com -
5 Things You Should Know Before the Stock Market Opens - TheStreet.com -
Carl Icahn Rumors Aren't a Reason to Buy Chesapeake Energy - TheStreet.com -
Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer - TheStreet.com -
Ex-Dividend Stocks: Goldman Sachs, Time Warner - TheStreet.com -
Stocks to Watch: VeriFone, Mentor Graphics - TheStreet.com -
Trina Solar Limited Stock Downgraded (TSL) - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
Perfect World to Announce First Quarter 2012 Financial Results on May 29, 2012 -
Marley Coffee Lends Support to Lightning in a Bottle Festival -
Ric Edelman Assumes Role of Chief Executive Officer of The Edelman Financial Group; Board Declares Quarterly Dividend -
Equity Residential Enters into Agreement with Owners of Archstone Equity Residential to Receive $150 Million -
Goodrich Petroleum To Present At Upcoming Conferences -
Synacor's Theodore May to Speak at CONNECTIONS: The Digital Living Conference Tuesday, June 5, 2012 -
Lehman Brothers to Acquire Partners’ Remaining Stake in Archstone -
Bank of America Enters Into Agreement to Sell Remaining Interest in Archstone









